Tozorakimab  (Synonyms: MEDI-3506)

Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease^[1].

Human IgG1 lambda2

Human IgG1 lambda2, Isotype Control

Human

IL-33

Tozorakimab (0.1-10 mg/kg, i.p., once time) inhibits IL-5 levels in bronchoalveolar lavage fluid of humanized IL-33 genetically modified mice in dose-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

90865  [NCBI]

O95760

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.66 kDa

2376858-66-9

Liquid

Colorless to light yellow

[Tozorakimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda

• 
  Immobilized Human IL-33 Protein can bind Tozorakimab. The EC₅₀ for this effect is 3.21 ng/mL.
• 
  Flow cytometric analysis of 1.5×10⁶ HUVEC cells with Tozorakimab (HY-P99550, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 lambda2 Isotype Control (HY-P990096, blue) was used as the isotype control.

• [1]. Reid F, et al. Safety, pharmacokinetics and immunogenicity of the anti-interleukin-33 antibody, tozorakimab: results of a phase 1 study in healthy adults and patients with chronic obstructive pulmonary disease. American Thoracic Society. 2022: A2398-A2398.

  [2]. England E, et al. Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023 Jun 17;13(1):9825.  [Content Brief]